Search

Many diseases have their treatment options narrowed and end up being fatal if detected during later stages. As a consequence, point-of-care devices have an increasing importance for routine screening applications in the health sector due to their portability, fast analyses and decreased cost. For that purpose, a multifunctional chip was developed and tested using gold nanoprobes to perform RNA optical detection inside a microfluidic chip without the need of molecular amplification steps. As a proof-of-concept, this device was used for the rapid detection of chronic myeloid leukemia, a hemato-oncological disease that would benefit from early stage diagnostics and screening tests. The chip passively mixed target RNA from samples, gold nanoprobes and saline solution to infer a result from their final colorimetric properties. An optical fiber network was used to evaluate its transmitted spectra inside the chip. Trials provided accurate output results within 3 min, yielding signal-to-noise ratios up to 9 dB. When compared to actual state-of-art screening techniques of chronic myeloid leukemia, these results were, at microscale, at least 10 times faster than the reported detection methods for chronic myeloid leukemia. Concerning point-of-care applications, this work paves the way for other new and more complex versions of optical based genosensors., Funding Agencies|FEDER funds through the COMPETE Programme; FCT - Portuguese Foundation for Science and Technology [POCI-01-0145-FEDER-007688, UID/CTM/50025/2013]; project DISERTOX [PTDC/CTM-NAN/2912/2014]; Unidade de Ciencias Biomoleculares Aplicadas - UCIBIO - FCT/MCTES [UID/Multi/04378/2013]; ERDF [POCI-01-0145-FEDER-007728, PD/BD/52211/2013]

Many diseases have their treatment options narrowed and end up being fatal if detected during later stages. As a consequence, point-of-care devices have an increasing importance for routine screening applications in the health sector due to their portability, fast analyses and decreased cost. For that purpose, a multifunctional chip was developed and tested using gold nanoprobes to perform RNA optical detection inside a microfluidic chip without the need of molecular amplification steps. As a proof-of-concept, this device was used for the rapid detection of chronic myeloid leukemia, a hemato-oncological disease that would benefit from early stage diagnostics and screening tests. The chip passively mixed target RNA from samples, gold nanoprobes and saline solution to infer a result from their final colorimetric properties. An optical fiber network was used to evaluate its transmitted spectra inside the chip. Trials provided accurate output results within 3 min, yielding signal-to-noise ratios up to 9 dB. When compared to actual state-of-art screening techniques of chronic myeloid leukemia, these results were, at microscale, at least 10 times faster than the reported detection methods for chronic myeloid leukemia. Concerning point-of-care applications, this work paves the way for other new and more complex versions of optical based genosensors., Funding Agencies|FEDER funds through the COMPETE Programme; FCT - Portuguese Foundation for Science and Technology [POCI-01-0145-FEDER-007688, UID/CTM/50025/2013]; project DISERTOX [PTDC/CTM-NAN/2912/2014]; Unidade de Ciencias Biomoleculares Aplicadas - UCIBIO - FCT/MCTES [UID/Multi/04378/2013]; ERDF [POCI-01-0145-FEDER-007728, PD/BD/52211/2013]

Many diseases have their treatment options narrowed and end up being fatal if detected during later stages. As a consequence, point-of-care devices have an increasing importance for routine screening applications in the health sector due to their portability, fast analyses and decreased cost. For that purpose, a multifunctional chip was developed and tested using gold nanoprobes to perform RNA optical detection inside a microfluidic chip without the need of molecular amplification steps. As a proof-of-concept, this device was used for the rapid detection of chronic myeloid leukemia, a hemato-oncological disease that would benefit from early stage diagnostics and screening tests. The chip passively mixed target RNA from samples, gold nanoprobes and saline solution to infer a result from their final colorimetric properties. An optical fiber network was used to evaluate its transmitted spectra inside the chip. Trials provided accurate output results within 3 min, yielding signal-to-noise ratios up to 9 dB. When compared to actual state-of-art screening techniques of chronic myeloid leukemia, these results were, at microscale, at least 10 times faster than the reported detection methods for chronic myeloid leukemia. Concerning point-of-care applications, this work paves the way for other new and more complex versions of optical based genosensors., Funding Agencies|FEDER funds through the COMPETE Programme; FCT - Portuguese Foundation for Science and Technology [POCI-01-0145-FEDER-007688, UID/CTM/50025/2013]; project DISERTOX [PTDC/CTM-NAN/2912/2014]; Unidade de Ciencias Biomoleculares Aplicadas - UCIBIO - FCT/MCTES [UID/Multi/04378/2013]; ERDF [POCI-01-0145-FEDER-007728, PD/BD/52211/2013]

Many diseases have their treatment options narrowed and end up being fatal if detected during later stages. As a consequence, point-of-care devices have an increasing importance for routine screening applications in the health sector due to their portability, fast analyses and decreased cost. For that purpose, a multifunctional chip was developed and tested using gold nanoprobes to perform RNA optical detection inside a microfluidic chip without the need of molecular amplification steps. As a proof-of-concept, this device was used for the rapid detection of chronic myeloid leukemia, a hemato-oncological disease that would benefit from early stage diagnostics and screening tests. The chip passively mixed target RNA from samples, gold nanoprobes and saline solution to infer a result from their final colorimetric properties. An optical fiber network was used to evaluate its transmitted spectra inside the chip. Trials provided accurate output results within 3 min, yielding signal-to-noise ratios up to 9 dB. When compared to actual state-of-art screening techniques of chronic myeloid leukemia, these results were, at microscale, at least 10 times faster than the reported detection methods for chronic myeloid leukemia. Concerning point-of-care applications, this work paves the way for other new and more complex versions of optical based genosensors., Funding Agencies|FEDER funds through the COMPETE Programme; FCT - Portuguese Foundation for Science and Technology [POCI-01-0145-FEDER-007688, UID/CTM/50025/2013]; project DISERTOX [PTDC/CTM-NAN/2912/2014]; Unidade de Ciencias Biomoleculares Aplicadas - UCIBIO - FCT/MCTES [UID/Multi/04378/2013]; ERDF [POCI-01-0145-FEDER-007728, PD/BD/52211/2013]

Many diseases have their treatment options narrowed and end up being fatal if detected during later stages. As a consequence, point-of-care devices have an increasing importance for routine screening applications in the health sector due to their portability, fast analyses and decreased cost. For that purpose, a multifunctional chip was developed and tested using gold nanoprobes to perform RNA optical detection inside a microfluidic chip without the need of molecular amplification steps. As a proof-of-concept, this device was used for the rapid detection of chronic myeloid leukemia, a hemato-oncological disease that would benefit from early stage diagnostics and screening tests. The chip passively mixed target RNA from samples, gold nanoprobes and saline solution to infer a result from their final colorimetric properties. An optical fiber network was used to evaluate its transmitted spectra inside the chip. Trials provided accurate output results within 3 min, yielding signal-to-noise ratios up to 9 dB. When compared to actual state-of-art screening techniques of chronic myeloid leukemia, these results were, at microscale, at least 10 times faster than the reported detection methods for chronic myeloid leukemia. Concerning point-of-care applications, this work paves the way for other new and more complex versions of optical based genosensors., Funding Agencies|FEDER funds through the COMPETE Programme; FCT - Portuguese Foundation for Science and Technology [POCI-01-0145-FEDER-007688, UID/CTM/50025/2013]; project DISERTOX [PTDC/CTM-NAN/2912/2014]; Unidade de Ciencias Biomoleculares Aplicadas - UCIBIO - FCT/MCTES [UID/Multi/04378/2013]; ERDF [POCI-01-0145-FEDER-007728, PD/BD/52211/2013]

Many diseases have their treatment options narrowed and end up being fatal if detected during later stages. As a consequence, point-of-care devices have an increasing importance for routine screening applications in the health sector due to their portability, fast analyses and decreased cost. For that purpose, a multifunctional chip was developed and tested using gold nanoprobes to perform RNA optical detection inside a microfluidic chip without the need of molecular amplification steps. As a proof-of-concept, this device was used for the rapid detection of chronic myeloid leukemia, a hemato-oncological disease that would benefit from early stage diagnostics and screening tests. The chip passively mixed target RNA from samples, gold nanoprobes and saline solution to infer a result from their final colorimetric properties. An optical fiber network was used to evaluate its transmitted spectra inside the chip. Trials provided accurate output results within 3 min, yielding signal-to-noise ratios up to 9 dB. When compared to actual state-of-art screening techniques of chronic myeloid leukemia, these results were, at microscale, at least 10 times faster than the reported detection methods for chronic myeloid leukemia. Concerning point-of-care applications, this work paves the way for other new and more complex versions of optical based genosensors., Funding Agencies|FEDER funds through the COMPETE Programme; FCT - Portuguese Foundation for Science and Technology [POCI-01-0145-FEDER-007688, UID/CTM/50025/2013]; project DISERTOX [PTDC/CTM-NAN/2912/2014]; Unidade de Ciencias Biomoleculares Aplicadas - UCIBIO - FCT/MCTES [UID/Multi/04378/2013]; ERDF [POCI-01-0145-FEDER-007728, PD/BD/52211/2013]